Business Context and Reporting Period
This Form 8-K is a Current Report filed by Synta Pharmaceuticals Corp. on June 13, 2013. The filing reports on corporate governance actions taken at the Company's Annual Meeting of Stockholders held on the same date. Note: The request metadata references "MADRIGAL PHARMACEUTICALS, INC.", but the source text explicitly identifies the registrant as Synta Pharmaceuticals Corp.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure amendments.
Material Changes
- Authorized Share Increase: The Company amended its Restated Certificate of Incorporation to increase authorized common stock from 100,000,000 to 200,000,000 shares. The amendment became effective immediately upon filing.
- Board Composition: Stockholders elected Safi R. Bahcall, Ph.D., and Bruce Kovner as Class III directors for three-year terms expiring in 2016.
- Accounting Firm: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2013.
Guidance, Outlook, and Management Commentary
The filing includes no financial guidance, outlook, or management commentary regarding business operations. Regarding executive compensation, the Board of Directors determined, consistent with stockholder votes, to hold a non-binding, advisory vote on executive compensation every year until the next required frequency vote (expected in 2019) or an earlier Board decision.
Important Facts for Investor Verification
- Verify the exact number of authorized shares increased to 200,000,000.
- Confirm the election of Safi R. Bahcall and Bruce Kovner to the Board of Directors.
- Note the approval of annual advisory votes on executive compensation.
- Review the Definitive Proxy Statement filed on April 29, 2013, for detailed background on the proposals.